Biocon reports Q2FY25 revenue of Rs 3,623cr amid generics pressure
Biocon Limited, a leading global biopharmaceutical company, released its consolidated financial results for Q2FY25, reporting a total revenue of Rs 3,623 crore. This represented a ... Read More
Eris Lifesciences acquires Biocon Biologics’ branded formulation business for Rs 1,242cr
In a strategic move that reshapes the landscape of India's injectables market, Eris Lifesciences Ltd., a leading player in the branded formulations sector, has announced ... Read More
Biocon Biologics secures license agreement for biosimilar launch in US
In a landmark announcement, Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd, revealed its settlement and license ... Read More
Sandoz and Biocon Biologics sign distribution deal for key immunology drug
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd and a prominent player in the global biosimilars market, has entered into a pivotal Distribution Agreement ... Read More
Biocon Biologics wraps up integration of Viatris’ biosimilars business in Europe
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced the successful completion of the integration of Viatris’ biosimilars business across 31 European countries. ... Read More
Biocon Biologics wraps up integration of former Viatris biosimilars business
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced the successful integration of the acquired biosimilars business from Viatris in over 70 countries ... Read More
Biocon Biologics debuts biosimilar HULIO in US market
In a significant development for healthcare accessibility, Biocon Biologics Ltd (BBL), a subsidiary of Biocon, announced the availability of its biosimilar injection, HULIO (adalimumab-fkjp), in ... Read More
FDA rejects Biocon Biologics BLA for Insulin-R product
Biocon Limited, an Indian biopharma company, said that its subsidiary Biocon Biologics has been issued a complete response letter (CRL) from the US Food and ... Read More
Biocon Biologics wraps up $3.3bn acquisition of Viatris biosimilars unit
Biocon said that its subsidiary Biocon Biologics has wrapped up the previously announced $3.3 billion acquisition of the biosimilars business of US-based pharma company Viatris. ... Read More
Biocon Biologics signs licensing deal for two biosimilars with Yoshindo
Biocon Ltd. said that its subsidiary Biocon Biologics has signed an out-licensing agreement with Japanese pharma company Yoshindo Inc. for commercializing a couple of its ... Read More